---
title: "CCHT: Clinical trial approval for the domestically produced injectable GenSci139"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261862093.md"
description: "According to the Zhitong Finance APP, Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\"), has received the \"Drug Clinical Trial Approval Notice\" approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of the injectable GenSci139 monotherapy in patients with advanced solid tumors"
datetime: "2025-10-20T10:54:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261862093.md)
  - [en](https://longbridge.com/en/news/261862093.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261862093.md)
generator: "portal-rs"
---

# CCHT: Clinical trial approval for the domestically produced injectable GenSci139

According to the Zhitong Finance APP, Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials of the injectable GenSci139 monotherapy in patients with advanced solid tumors

### Related Stocks

- [000661.CN](https://longbridge.com/en/quote/000661.CN.md)

## Related News & Research

- [Lean and Mathlib Communities Verify Levent Alpöge’s Riemann Hypothesis Proof](https://longbridge.com/en/news/306379574.md)
- [Hanil Feed's (KOSDAQ:005860) Conservative Accounting Might Explain Soft Earnings](https://longbridge.com/en/news/306378716.md)
- [The Strong Earnings Posted By Shree Ajit Pulp and Paper (NSE:SAPPL) Are A Good Indication Of The Strength Of The Business](https://longbridge.com/en/news/306380802.md)
- [Starknet: Scheduled unlock releases up to 127 million STRK - 15 Dec 2026](https://longbridge.com/en/news/306371387.md)
- [OBSBOT stellt Tail 2 ADV und Tail Air 2 vor: Erweiterung der kreativen Freiheit für professionelle Produktionsteams und Kreative](https://longbridge.com/en/news/306372789.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**